NeuroNova AB

NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Its products include sNN0029, a drug candidate for the treatment of amyotrophic lateral sclerosis; and sNN0031, a drug candidate for the treatment of moderate to severe stage Parkinson’s disease that is designed to act on neural stem and progenitor cells in the brain.